Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-101
- Development stage
- Phase 2
- Lead developer
- Serenity Bioworks
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SER-101 (formerly DC-TAB) is a recombinant human HspB5 (alpha-B crystallin) protein therapeutic being developed by Serenity Bioworks for the treatment of severe autoimmune disorders. HspB5 is a small heat shock protein that acts as a molecular chaperone and a potent immunomodulator. It specifically targets myeloid cells, such as macrophages and microglia, to inhibit the production of pro-inflammatory cytokines and promote an anti-inflammatory state. Originally developed by Delta Crystallon, the asset completed a Phase I/IIa clinical trial in multiple sclerosis, demonstrating safety and preliminary efficacy. Serenity Bioworks is currently repurposing the drug for Phase II development in lupus nephritis, supported by preclinical evidence in lupus models.
- Other names
- recombinant human HspB5alpha-B crystallinCRYAB
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on SER-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-101.